Ovarian cancer biomarker blood test study
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study is testing new blood tests that might help detect ovarian cancer earlier by looking for specific markers. It involves people with suspected ovarian cancer and healthy volunteers, and aims to improve how we diagnose the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 35 years or older
- You have female reproductive organs (including women, trans men, and non-binary people)
- You either have a suspected ovarian mass that will be removed or biopsied, or you have been diagnosed with ovarian cancer and haven't had surgery or treatment yet
- Or you are a healthy volunteer with no history of cancer
- You are able to give informed consent
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at tumor tissue from ovarian cancer patients to find “biomarkers,” or lab signals, that may predict how the disease behaves or how it might respond to treatment. You may be asked for a biopsy of the relapsed (coming back) tumor or to use an existing archived tumor sample.
This study uses a custom lab test on blood (and tumor tissue) to track ovarian cancer returning and to see how well treatment is working. It may help your care team monitor changes over time, especially after certain surgeries.
This study is testing a new blood test to help find ovarian cancer early in women who are at average risk. By joining, you may help improve early detection, which could lead to better outcomes.
This study is testing a blood test to see if it can catch ovarian cancer early. You may be eligible if you have been recently diagnosed with ovarian cancer and haven't started treatment yet.
This trial tests a new blood test (OCS) that may help detect if ovarian cancer comes back after initial treatment. It is for people whose CA125 levels were normal at diagnosis.
This study is testing a new blood test (called the EARLY panel) to see how well it can detect ovarian cancer in postmenopausal women aged 50–74. It aims to find out if the test is accurate and practical for routine screening.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.